Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Table 1 Clinical characteristics of the patients with cirrhosis and hepatocellular carcinoma enrolled in the study n (%)

Characteristics	n = 44
Age (yr)
mean (SD)	67.7 (10.1)
median (min-max)	70 (44-83)
Males	38 (86.4)
Recruiting unit
Hepatology	29 (65.9)
Medical Oncology	15 (34.1)
Etiology of cirrhosis
HCV	19 (43.2)
HBV	9 (20.5)
Alcohol	7 (15.9)
Multifactorial	4 (9.1)
Cryptogenic	4 (9.1)
Primary biliary cirrhosis	1 (2.3)
ECOG performance status
0	24 (54.5)
1	18 (40.9)
2	2 (4.5)
BCLC
B	15 (34.1)
C	29 (65.9)
Child-Pugh class
A	29 (65.9)
B	15 (34.1)
Extrahepatic spread	9 (20.5)
Portal vein thrombosis	8 (18.2)
Varices	15 (34.1)
Macroscopic category
Extrahepatic only	1 (2.3)
Uninodular	3 (6.8)
≤ 3 nodules	34 (77.3)
> 3 nodules	6 (13.6)
Previous therapies
TACE1	20 (45.5)
Locoregional ablation	3 (6.8)
Surgical resection	2 (4.5)
None	19 (43.2)

¹Includes 7 patients in whom trans arterial chemio-embolization (TACE) was performed in combination with other treatment modalities, and 2 patients treated with ⁹⁰Y radio-embolization. HCV: Hepatitis C virus; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinic liver cancer.